Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warning Eclipses Sun, SPARC But Investors Stand Pat

This article was originally published in Scrip

Executive Summary

Shares of Sun Pharmaceutical Industries Ltd and Sun Pharma Advanced Research Company Ltd (SPARC) were pounded in early trade Dec. 21 on Indian bourses after the weekend announcement of an FDA warning letter for Sun's Halol site, though analysts appeared cautiously optimistic about the firm's bounce-back prospects despite the short-term pain.

Advertisement

Related Content

Baclofen Setback Forces Sun R&D Arm Towards Difficult Choices
Keeping Track: New Submissions In Bladder Cancer, HCV And Diabetes; Avastin Label Expands
SPARC Pins Hope On Halol Plant For Elepsia FDA Nod But Has Plan B

Topics

Advertisement
UsernamePublicRestriction

Register

SC064040

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel